Ahmed, Usaid MBBSa; Afaq, Laiba MBBSa; Muhammad, Aqeel MBBSa; Riaz, Rumaisa MBBSa; Akilimali, Aymar MDb. Evaluating the therapeutic efficacy of SKYCLARYS: a promising FDA-approved drug for Friedreich ataxia treatment. International Journal of Surgery: Global Health 7(1):e0394, January 2024. | DOI: 10.1097/GH9.0000000000000394
Omaveloxone’s activation of the Nrf2 pathway, responsible for combating oxidative stress, has shown significant promise, especially in enhancing neurological function. Continuous research and the accumulation of clinical knowledge will play a crucial role in fine-tuning its best practices and investigating potential synergies with other treatments, all with the goal of further advancing the outcomes for those living with FRDA.
